Kiromic Biopharma Inc (KRBP) Peer Comparison
$0.04
$0.00 (0.00%)As on 13-Jun-2025 09:30EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
11.5
Div. Yield
0 %
Edit
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
0 | 16,765 | 16,261 | 13,492 | 12,332 |
Revenue ($ Mln) |
-- | 2,782 | 1,054 | 2,436 | 1,284 |
Net Profit ($ Mln) |
-26.90 | 491.50 | 755.85 | 860.62 | -325.10 |
Net Margin (%) |
-- | 17.67 | 71.69 | 35.33 | -25.32 |
RoE (%) |
247.82 | 110.09 | -- | 42.98 | -57.72 |
Price to Earnings |
-- | 35.25 | 19.00 | 17.40 | -- |
Price-To-Book |
11.55 | 39.29 | 9.76 | 7.42 | 23.98 |
Income Statement ($ Mln)
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 2,109.05 | 363.64 | 2,168.70 | 180.13 |
|
Cost of Revenue
|
8.07 | 1,452.75 | 44.26 | 76.22 | 6.23 |
|
Gross Profit
|
-8.07 | 656.31 | 319.38 | 2,092.49 | 173.90 |
|
Operating Expenses
|
23.77 | 209.44 | 598.15 | 1,487.87 | 671.78 |
|
Operating Profit (EBIT)
|
-23.77 | 446.87 | -278.76 | 604.62 | -497.88 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-26.90 | 475.92 | -373.24 | 681.64 | -465.89 |
|
Provision for Tax
|
-- | 71.54 | 4.84 | 160.37 | -465.89 |
|
Profit after Tax (Net Income)
|
-26.90 | 404.39 | -378.08 | 521.27 | -465.89 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-12.59 | 825.55 | -105.71 | 2,244.20 | 754.38 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.23 | 170.77 | 377.34 | 299.72 | 118.59 |
|
Current Liabilities
|
20.90 | 1,104.55 | 907.86 | 403.77 | 169.28 |
|
Total Liabilities
|
8.55 | 2,100.87 | 1,179.50 | 2,947.69 | 1,042.25 |
Assets ($ Mln)
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
5.24 | 1,071.64 | 118.63 | 1,480.11 | 9.32 |
|
Current Assets
|
3.30 | 1,029.23 | 1,060.86 | 1,467.58 | 1,032.93 |
|
Total Assets
|
8.55 | 2,100.87 | 1,179.50 | 2,947.69 | 1,042.25 |
|
Total Debt*
|
14.57 | 149.52 | 856.62 | 190.82 | 119.57 |
|
Net Current Assets
|
-17.60 | -75.32 | 153.00 | 1,063.81 | 863.65 |
Cashflow ($ Mln)
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-19.46 | 608.82 | -306.20 | 699.97 | -455.57 |
|
Cash Flow from Investing Activities
|
-0.37 | -28.31 | 6.88 | -116.78 | -274.39 |
|
Cash from Financing Activities
|
18.42 | -154.01 | 443.93 | -628.81 | 735.06 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-640.22 | 48.25 | -56.08 | 21.32 | -66.72 |
|
ROE (%)
|
247.82 | 58.42 | 300.78 | 23.13 | -80.35 |
|
ROA (%)
|
-259.71 | 21.52 | -37.71 | 17.70 | -55.37 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 19.17 | -103.97 | 24.04 | -258.64 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.12 | 0.36 | 0.18 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-26.32 | 42.99 | 21.47 | 150.89 | -24.69 |
|
EPS Growth (%)
|
-0.46 | 0.42 | 0.26 | 1.79 | -0.12 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.95 | 26.30 | -21.77 | 18.00 | -14.52 |
|
Price / Book Value
|
-2.04 | 12.88 | -77.86 | 4.18 | 8.97 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-1.64 | 20.03 | -29.40 | 11.77 | -13.24 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.16 | 0.18 | -8.10 | 0.09 | 0.16 |
|
Short term debt to equity ratio
|
-1.14 | 0.03 | -4.65 | 0.01 | 0.00 |
|
Current Ratio
|
0.16 | 0.93 | 1.17 | 3.63 | 6.10 |
|
Quick Ratio
|
-- | -- | 0.84 | 3.58 | 5.90 |
|
Interest Coverage
|
-8.22 | 19.04 | -4.70 | -- | -30.76 |
Operating Efficiency Ratios
| Kiromic Biopharma Inc (KRBP) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 14.06 | 45.73 | 12.24 | 29.88 |
|
Asset Turnover
|
0.00 | 1.12 | 0.36 | 0.74 | 0.21 |
|
Receivable days
|
-- | 51.51 | 101.52 | 42.34 | 54.57 |
|
Inventory Days
|
-- | 0.00 | 2,081.92 | 95.15 | 998.18 |
|
Payable days
|
108.94 | 8.10 | 787.97 | 172.42 | 2,099.03 |
|
Cash Conversion Cycle
|
-- | 43.41 | 1,395.47 | -34.93 | -1,046.28 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
